<DOC>
	<DOCNO>NCT01361958</DOCNO>
	<brief_summary>The aim present study evaluate ability several dos NOMAC combination E2 inhibit ovulation ass change gonadotropin ovarian hormone profile , comparison control cycle healthy-volunteer premenopausal woman . The study also design check whether combined administration E2 NOMAC dose 2.5 mg daily induces change effect progestin compare give alone .</brief_summary>
	<brief_title>Minimal Effective Dose Nomegestrol Acetate Inhibiting Ovulation Women Receiving Estradiol</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<criteria>Female premenopausal healthy volunteer give informed write consent first selection visit , Registered Social Security agreement French Law biomedical research volunteer , Sufficiently cooperative meet need study , Accepting become pregnant trial , Accepting use condom single authorize contraceptive mean trial , With diurnal regular job activity , Aged 18 35 year old inclusive , Nonsmokers current smoker less 10 cigarettes/day , With normal eat habit , With body mass index 17 27 inclusive , Participation another clinical trial , Blood donation three month prior Visit V1 intention donate blood trial within three month follow trial completion , Virgins , gynecological examination , Subjects within exclusion period Healthy Volunteers National Register French Ministry Health , Forfeiture freedom administrative legal award guardianship , No possible contact case emergency , Strenuous physical activity plan trial . Concerning gynecological status examination History major medical , psychiatric illness surgery , Any acute chronic systemic disease disorder , History hypersensitivity least one drug ( abnormal drug reaction idiosyncrasy asthma ) , Abuse alcohol i.e . history evidence acute chronic abuse , 45 g alcohol per day , Excessive drinking tea , coffee , chocolate , and/or beverage contain caffeine ( &gt; 5 cups/day approximately 500 mg caffeine per day ) , Current vascular pathology past history thromboembolic disease , arterial hypertension ( BPS ≥ 160 mm Hg BPD ≥ 95 mm Hg ) , coronary artery disease , valvulopathy ; thrombogenic cardiac rhythm disturbance , cerebrovascular disease , ocular pathology vascular origin , Cancer progressive hematological disorder , Current past history pituitary tumor , Epilepsy , Known hyperprolactinemia , Known renal insufficiency , Severe recent liver disease symptomatic vesicular lithiasis , recurrent cholestasis recur pruritus pregnancy , Abnormality ( &gt; 1N ) liver function selection laboratory investigation ( ALT AST &gt; 50 IU/L alkaline phosphatases &gt; 125 IU/L total bilirubin &gt; 22 μmol/L GGT &gt; 70 IU/L ) , Known diabetes fast blood sugar &gt; 6.2 mmol/L ( 1N ) selection laboratory investigation , Uncontrolled treat dyslipidemia cholesterolemia &gt; 5.2 mmol/L ( 93 % N ) , &gt; 6.2 mmol/L ( 110 % N ) protocol amendment course study , triglyceridemia &gt; 1.80 mmol/L ( 79 % N ) selection laboratory investigation , Plasma creatinine &gt; 115 μmol/L ( 1N ) , Abnormality hematology parameter , Positive result serology ( HBs antigen , HCV antibody , HIV 1 &amp; 2 antibody ) perform V1 , Positive result βHCG measurement ( i.e . βHCG &gt; 5 mIU/mL ) , Abnormality baseline EKG , Connective tissue disorder , Porphyria , Otosclerosis , Abnormality medical examination perform V1 include neurological examination , Past history clinical evidence malignant tumor benign disease breast uterus ovary ( include endometriosis , leiomyoma , polycystic ovary ... ) , Vaginal infection vaginal bacteriological examination perform V1 . After protocol amendment course study , infection diagnose vaginal bacteriology cervicovaginal smear remove exclusion criterion list . Hysterectomy , even partial , endometrectomy , Pregnancy , Childbirth , breastfeeding , miscarriage termination pregnancy year prior V1 ,</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>